ClearOne is trading 7% down today at $7.80 as investors continue to digest its highly dilutive reverse merger with Vivani Medical’s Cortigent unit and related legal scrutiny.
- The stock is extending a sharp pullback following an outsized multi-day surge triggered by the initial merger announcement.
- Selling pressure is being driven by a shareholder-rights investigation into deal fairness alongside ongoing profit-taking.